Molecule Details
| InChIKey | FQPQMJULRZINPV-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | Cc1cnc(-c2ccnc(C(C)(C)O)n2)cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.68 |
| Source | BindingDB;ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16502 |
|---|---|
| Drug Name | Zunsemetinib |
| CAS Number | 1640282-42-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. Zunsemetinib ... |
Categories: Experimental Unapproved Treatments for COVID-19
Cross-references: BindingDB: 175242 CHEMBL3704901 ChemSpider: 58947940 ZINC: ZINC000220110608
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P49137 | MAPKAPK2 | MAP kinase-activated protein kinase 2 | inhibitor | targets |